Mircea Manuc

Prof. Dr. Mircea Manuc


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2017 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
MCMaria Ciocîrlan
Maria Ciocîrlan
ACAndreea Ruxandra Cazan
Andreea Ruxandra Cazan
MBMihaela Barbu
Mihaela Barbu
MMMircea Manuc
Mircea Manuc
MDMihai Mircea Diculescu
Mihai Mircea Diculescu
MCMihai Ciocîrlan
Mihai Ciocîrlan
Background and Aims. Malnutrition is common in patients with chronic liver disease. We aimed to evaluate malnutrition assessment tools in predicting severity and survival of patients with liver cirrhosis. Material and Methods. We examined patients with liver cirrhosis. Nutritional evaluation was performed on admission, using subjective global assessment (SGA), handgrip strength (HGS), and anthropometry. Patients were followed up for 6 months. Results. We included 100 patients, 72 men, with mean age of 59.2 years. According to disease severity, patients were 23% Child-Pugh A, 46% Child-Pugh B, and 31% Child-Pugh C. SGA and HGS significantly correlated with Child-Pugh, MELD, and MELD-Na scores on admission. At 6 months follow-up, 80.4% (78 of 97) of patients survived, while 3 patients were lost from observation. Survival was predicted by SGA (1 death in 32 patients SGA A, 8 deaths in 46 patients SGA B, and 9 deaths in 19 patients SGA C, p=0.001) and HGS (25.1 ± 8.5 in deceased versus 30.6 ± 10.9 in survivors, p=0.046). The mean BMI and MAMC values did not significantly differ between patients who survived or were deceased at 6 months. Conclusion. HGS and SGA may predict severity and short-term survival in cirrhotic patients.

1 January 2020 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
EMElena Milanesi
Elena Milanesi
MDMaria Dobre
Maria Dobre
ABAlina Ioana Bucuroiu
Alina Ioana Bucuroiu
VHVlad Herlea
Vlad Herlea
TMTeodora Ecaterina Manuc
Teodora Ecaterina Manuc
GBGabriel Becheanu
Gabriel Becheanu
MicroRNAs (miRNAs) have been proposed as promising molecular biomarkers for diagnosis, prognosis, and responsive therapeutic targets in different types of cancer, including colorectal cancer (CRC). In this study, we evaluated the expression levels of 84 cancer‐associated miRNAs in a cohort of 39 human samples comprising 13 peritumoral and 26 tumoral tissues from surgical specimens of CRC patients. KRAS mutations were detected in 11 tumoral samples. In a first analysis, we found 5 miRNAs (miR‐215‐5p, miR‐9‐5p, miR‐138‐5p, miR378a‐3p, and miR‐150‐5p) that were significantly downregulated and one upregulated (miR‐135b‐5p) in tumoral tissues compared with the peritumoral tissues. Furthermore, by comparing miRNA profile between KRAS mutated CRC tissues respect to wild type CRC tissues, we found 7 miRNA (miR‐27b‐3p, miR‐191‐5p, miR‐let7d‐5p, miR‐15b‐5p, miR‐98‐5p, miR‐10a‐5p, and miR‐149‐5p) downregulated in KRAS mutated condition. In conclusion, we have identified a panel of miRNAs that specifically distinguish CRC tissues from peritumoral tissue and a different set of miRNAs specific for CRC with KRAS mutations. These findings may contribute to the discovering of new molecular biomarkers with clinic relevance and might shed light on novel molecular aspects of CRC.

29 March 2024 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
MMMircea Manuc
Mircea Manuc
MDMihai Mircea Diculescu
Mihai Mircea Diculescu
EDEugen Dumitru
Eugen Dumitru
Dan Ionuţ GheoneaDan Ionuţ Gheonea
Dan Ionuţ Gheonea
MJMariana Jinga
Mariana Jinga
CGCristian Gheorghe
Cristian Gheorghe
Background and Aims: Colorectal cancer (CRC) is the third cause of cancer-related death worldwide. Screening programs can reduce CRC mortality rates by up to 60%. In line with the European Union recommendations, Romania started the first four regional pilot screening programs in 2020 (the ROCCAS II projects). This study reports the interim screening performance indicators. Methods: People aged 50 to 74 years were invited to the screening program. General practitioners (GPs) evaluated CRC risk based on a survey. High-risk or symptomatic individuals were referred directly to colonoscopy. The average risk participants received a fecal immunochemical test (FIT). Positive cases were invited to colonoscopy. Three regions were screened using the OC-SENSOR® (South-Muntenia, Bucharest-Ilfov, South-East) and one region (South-West) used the FOB GOLD®. The data was collected in the ROCCAS screening electronic registry. The following FIT parameters were evaluated: rates of return, invalidity, positivity, and colonoscopy acceptance rate according to age group, gender, region of provenience, and vulnerability status. Results: We included all cases screened between January 1, 2022 and September 30, 2023. In total, 168,958 people received the FIT test within the projects. The global FIT return rate was 90%. Factors associated with a higher return rate were female gender (90.77% vs 88.83%, p<0.0001), vulnerable status (91.23% vs 88.83%; p<0.00001), and rural residence (91.84% vs 88.42%, p<0.00001). The overall positivity rate was 5.75%. It was higher in males (7.64% vs 4.57% in females, p<0.00001) and progressively increased with the age group. The total invalid FIT rate was 5.87%, significantly lower for OC-SENSOR® (2.24%) than for the FOB GOLD® (13.6%). The overall acceptability rate for colonoscopy was 51.3%. Conclusions: According to our preliminary data, GP’s participation in the pilot programs ensured adequate adherence to screening through FIT. The rate for FIT return and positivity were acceptable for both tests, while the invalid rate was much higher in FOB GOLD® compared to the OC-SENSOR®. Moreover, colonoscopy acceptance needs to be improved. Our preliminary analysis revealed the screening performance indicators meet the EU recommendations and fulfill the premises for national-level expansion of the program starting in 2024.

9 February 2023 in Medicina
Verified
Journal Article
Open access
PDF file
MARIA NITESCUMARIA NITESCU
MARIA NITESCU
DIDoina Istratescu
Doina Istratescu
CPCarmen Monica Preda
Carmen Monica Preda
TMTeodora Ecaterina Manuc
Teodora Ecaterina Manuc
ELEdouard Louis
Edouard Louis
MDMihai Mircea Diculescu
Mihai Mircea Diculescu
Background and Objectives: Inflammatory bowel diseases are a main focus in current research, with diet being an emerging therapeutic line due to its links in both onset and progression. A Western-style diet high in processed foods, food additives, red meat, and animal fat has been linked to a higher risk of developing IBD. The aim of this study was to establish an association between an anti-inflammatory exclusion diet and maintenance of remission in IBD. Also, we assessed the efficacy and safety of this diet compared to a non-dietary group and the possible therapeutic effect of this diet in the maintenance of IBD remission. Materials and Methods: A total of 160 patients with IBD were screened for inclusion, but 21 did not met the inclusion criteria. Thus, 139 patients were assigned to either an exclusion diet or a regular diet according to their choice. Results: Clinical remission after six months was maintained in the exclusion diet arm (100%). In the control arm, four patients had clinically active disease (one patient with UC and three with CD), and 90 patients maintained the clinical remission state (95.7%) (p-value = 0.157). Regarding biochemical markers, ESR at baseline was higher in the exclusion diet arm: 29 (5–62) versus in the control arm 16 (4–48) (p-value = 0.019), but six months after, the groups were similar (p-value = 0.440). Conclusions: Patients who followed an exclusion diet maintained clinical remission more frequently. However, the threshold for statistical significance was not achieved. There was also a trend of improvement in inflammation tests in the intervention group.

7 November 2019 in Sao Paulo Medical Journal
Verified
Journal Article
Open access
PDF file
MCMaria Ciocîrlan
Maria Ciocîrlan
MMMircea Manuc
Mircea Manuc
MDMihai Mircea Diculescu
Mihai Mircea Diculescu
MCMihai Ciocîrlan
Mihai Ciocîrlan
KEY WORDS: Liver cirrhosis; Sarcopenia; Ultrasonography; Rectus abdominis

29 June 2024 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
PDF file
CPCarmen Monica Preda
Carmen Monica Preda
DIDoina Istratescu
Doina Istratescu
MARIA NITESCUMARIA NITESCU
MARIA NITESCU
TMTeodora Ecaterina Manuc
Teodora Ecaterina Manuc
MMMircea Manuc
Mircea Manuc
MDMihai Mircea Diculescu
Mihai Mircea Diculescu
Background and Aims: Recent research has shown that Western-style diets have been associated with an increased risk of inflammatory bowel diseases (IBD). Our aim was to examine the link between an anti-inflammatory diet and the maintenance of IBD remission, as well as to assess the potential therapeutic advantages of this dietary approach in preserving IBD remission. Methods: The inclusion and exclusion criteria were applied to a total of 189 individuals with IBD, with 21 individuals not meeting the criteria. Therefore, 168 eligible patients were enrolled in the study and allocated to either an anti-inflammatory diet or a regular diet, based on their personal preference. Results: A cohort of 168 IBD adult patients was recruited for the study: 88 patients with ulcerative colitis and 80 with Crohn‘s disease. The intervention group received an anti-inflammatory diet consisting of the removal of red and processed meat, fried foods, high-lactose foods, fast food, white bread, sugar, and vegetable oils rich in omega-6 for a period of 1 year. The clinical response was maintained in 80 patients (95.2%) in the intervention group and in 72 patients (85.7%) in the control group (p-value=0.036). Although not statistically significant, fecal calprotectin was higher in the control group than in the intervention group at follow-up. Conclusions: Patients who adhered to an anti-inflammatory diet exhibited a higher rate of maintenance of clinical remission. Furthermore, improvement in inflammation tests was observed in the intervention group, reinforcing the proposition that IBD is a lifestyle-related disease.